Publicaciones en las que colabora con Nerea Varo Cenarruzabeitia (22)

2015

  1. Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study

    International Journal of Cardiology, Vol. 185, pp. 177-185

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

2012

  1. The influence of obesity on the assessment of carotid intima-media thickness

    Journal of Clinical Ultrasound, Vol. 40, Núm. 8, pp. 479-485

2010

  1. Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension

    Journal of Hypertension, Vol. 28, Núm. 11, pp. 2219-2226

  2. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension (Clinical Science (2009) 116, (233-240))

    Clinical Science

2009

  1. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension

    Clinical Science, Vol. 116, Núm. 3, pp. 233-240

2008

  1. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome

    American Journal of Physiology - Endocrinology and Metabolism, Vol. 294, Núm. 1

  2. Response to association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity [4]

    Hypertension

  3. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin

    Journal of Clinical Endocrinology and Metabolism, Vol. 93, Núm. 6, pp. 2319-2327

2007

  1. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?

    Cardiovascular Research, Vol. 75, Núm. 3, pp. 536-545

2006

  1. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis

    Journal of the American College of Cardiology, Vol. 47, Núm. 7, pp. 1369-1378

2005

  1. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?

    Journal of Hypertension, Vol. 23, Núm. 3, pp. 625-632

  2. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients

    Journal of Hypertension, Vol. 23, Núm. 12, pp. 2297-2304

2002

  1. Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives

    Hypertension, Vol. 39, Núm. 4, pp. 923-928

2001

  1. Biochemical assessment of myocardial fibrosis in hypertensive heart disease

    Hypertension

  2. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients

    Circulation, Vol. 104, Núm. 3, pp. 286-291

2000

  1. Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats

    Hypertension, Vol. 35, Núm. 6, pp. 1197-1202

  2. Diagnóstico bioquímico de la fibrosis miocárdica hipertensiva

    Revista Espanola de Cardiologia, Vol. 53, Núm. SUPPL. 1, pp. 8-13

  3. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease

    Circulation, Vol. 101, Núm. 14, pp. 1729-1735

  4. Transforming growth factor β in hypertensives with cardiorenal damage

    Hypertension, Vol. 36, Núm. 4, pp. 517-522